Pfizer Receives Good News for Trazimera (trastuzumab) Biosimilar

Pfizer Receives Good News for Trazimera (trastuzumab) Biosimilar

Source: 
CP Wire
snippet: 

Pfizer Inc. (NYSE:PFE) announced on 6/1/2018 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for Trazimera, a potential biosimilar to Herceptin (trastuzumab), for the treatment of HER2 overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.